Skip to content
Sign in
Health · Global

Lilly says retatrutide outperformed Ozempic on blood sugar and weight

Eli Lilly said its investigational drug retatrutide performed better than Novo Nordisk’s Ozempic at lowering blood sugar and weight in a diabetes study. STAT described the study as large but gave no numerical results.

AI-assisted synthesis · Based on 4 independent reports from 5 outlets · Article text read from 1 of 4 reportsHow it's made

View timeline · 7 entries
5 outlets2 regionsLatest reporting 2 min read
Coverage: Center OnlyL 0 · C 5 · R 0

What happened

Key facts

  • Eli Lilly said its investigational drug retatrutide outperformed Novo Nordisk’s Ozempic in a diabetes study.
  • Lilly said retatrutide was more effective at lowering blood sugar and reducing weight.
  • The study was described as large.

The brief

Eli Lilly said its investigational medicine retatrutide performed better than Novo Nordisk’s Ozempic at lowering blood sugar and reducing weight in a diabetes study, according to STAT. STAT described the study as large. The announcement centers on Lilly’s comparison of the two medicines and the outcomes it said favored retatrutide.

STAT reported that Lilly made the announcement that morning. The account identifies the companies and medicines, and says the comparison took place in a diabetes study. It describes retatrutide as investigational; it does not report that Lilly said the medicine was approved or available as a treatment. The reported outcomes were blood sugar and weight.

STAT’s account gives no numerical results for either outcome, so the size of the reported differences cannot be specified. It also supplies no participant count or further description of the study’s design. The headlines from USA Today and Reuters likewise describe retatrutide as outperforming Ozempic on weight and blood sugar control.

FirstWord Pharma characterizes the work as a head-to-head diabetes study, while UA.NEWS says Lilly reported an outperformance in a diabetes study. Those headline descriptions do not add study measurements or other results. Lilly’s statement, as reported by STAT, presents the outcome as a comparison favoring its investigational medicine over Novo Nordisk’s Ozempic.

The account does not include a response from Novo Nordisk or a separate assessment of the findings. Accordingly, the reported result remains Lilly’s stated finding about the study, rather than a quantified comparison in the information reported here. The report does not provide the study’s results beyond the stated direction of the blood-sugar and weight comparison.

It therefore supports saying that Lilly reported better outcomes for retatrutide on those measures, but not describing the magnitude of the difference or other study findings.

Why it matters

  • The comparison concerns blood sugar and weight, two specific outcomes Lilly said favored retatrutide over Ozempic.
  • Lilly described retatrutide as investigational, placing its reported study comparison before any reported approval or availability.
  • STAT characterized the diabetes study as large, but the reported account supplies no participant count or numerical outcome results.

What to watch next

  • Whether Eli Lilly reports numerical blood-sugar and weight results from the study.
  • Whether Eli Lilly provides the study’s participant count or further design details.
  • Whether Novo Nordisk comments on the comparison with Ozempic.

How it's being covered

Coverage analysisShow details
5 source articles · 5 unique outlets · 4 distinct reports
Outlet political mix: Center Only· 5 Center
Where the outlets are based: US/Canada 40% · Europe 20% · Other 40%
Outlet political mix
Center Only
Left
Center
Right
0 outlets
5 outlets
0 outlets
The marker shows coverage balance: each unique outlet counts once.
Geography
Where the outlets covering this story are based.
5 unique outletsDominant coverage: US/Canada
Coverage imbalance
  • Coverage is currently concentrated among Center-rated outlets (5 of 5 rated sources); comparatively few Left or Right-rated outlets have published on the event.
How we measure coverage

One source is from a wire service (AP, Reuters, AFP or Bloomberg), whose reporting other outlets often republish.

How outlets' accounts compare

Updat3 does not yet have enough full reports to compare how outlets framed this story.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. The FDA approved exenatide, the first GLP-1 receptor agonist for type 2 diabetes, in 2005.
    Background · from our historical context
  2. Before retatrutide entered clinical testing, Novo Nordisk’s semaglutide had become an established treatment for type 2 diabetes: the U.S. Food and Drug Administration approved Ozempic for that use in December 2017.
    Background · from our historical context
  3. The FDA approved the higher-dose semaglutide product Wegovy for chronic weight management in June 2021.
    Background · from our historical context
  4. The FDA approved Eli Lilly’s tirzepatide as the diabetes treatment Mounjaro.
    Background · compiled and fact-checked by Updat3
  5. Lilly began studying it in humans before its phase 2 results were published in 2023.
    Background · from our historical context
  6. Researchers published a phase 2 trial of retatrutide in adults with type 2 diabetes, comparing it with placebo and dulaglutide.
    Background · compiled and fact-checked by Updat3
  7. A phase 2 trial in adults with obesity, published in the *New England Journal of Medicine* in July 2023, examined weight change over 48 weeks; it did not compare retatrutide with Ozempic in a diabetes trial.
    Background · from our historical context

How we got here

Before retatrutide entered clinical testing, Novo Nordisk’s semaglutide had become an established treatment for type 2 diabetes: the U.S. Food and Drug Administration approved Ozempic for that use in December 2017. The FDA approved the higher-dose semaglutide product Wegovy for chronic weight management in June 2021.

Lilly began studying it in humans before its phase 2 results were published in 2023. A phase 2 trial in adults with obesity, published in the *New England Journal of Medicine* in July 2023, examined weight change over 48 weeks; it did not compare retatrutide with Ozempic in a diabetes trial.

Original sources

1 of 5 articles · Europe · Show all

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.